Dear Healthcare Professional:

This letter is to inform you of recent changes in the KYNAMRO® (mipomersen sodium) injection Risk Evaluation and Mitigation Strategy (REMS) Program. To continue to prescribe KYNAMRO, healthcare professionals must recertify in the KYNAMRO REMS Program by Month, Day, 2017.

**Action Required**

All currently enrolled healthcare professionals must recertify by Month, Day, 2017 in order to continue to prescribe KYNAMRO. To recertify in the KYNAMRO REMS Program, healthcare professionals must:

- **Review** the KYNAMRO Prescribing Information and the **KYNAMRO REMS Program: An Introduction**.
- **Complete** the updated **KYNAMRO REMS Program Certification Training Module** and successfully complete the Knowledge Assessment.
- **Enroll** in the KYNAMRO REMS program by completing the **KYNAMRO REMS Program Prescriber Enrollment Form** and submit to the KYNAMRO REMS Program Coordinating Center.

**How To Enroll or Re-Certify in the KYNAMRO REMS Program**

- Call the KYNAMRO REMS Program Coordinating Center at 1-877-596-2676.
- Contact your Kastle Clinical Science Specialist
- Learn more at [www.KYNAMROREMS.com](http://www.KYNAMROREMS.com) KYNAMRO REMS Program Changes

The KYNAMRO REMS Program now has additional requirements for both healthcare professionals and patients. Before prescribing KYNAMRO you must:

1. **Review** the **KYNAMRO REMS Program Patient Guide** with each patient to counsel the patient about the appropriate use and risks associated with KYNAMRO and provide a copy to the patient.
2. **Complete** the **KYNAMRO REMS Program Patient - Prescriber Acknowledgment Form** with each patient, and submit it to the KYNAMRO REMS Program Coordinating Center.
3. **Prescribe** KYNAMRO for each patient by completing the **KYNAMRO REMS Program Prescription Authorization Form** and submit to the KYNAMRO REMS Program Coordinating Center.

Please see the accompanying Prescribing Information for your reference. As always, please report any adverse events to Kastle Drug Info at 1- 877-279-2308 or the FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch)

Sincerely,

Stuart Kupfer
Chief Medical Advisor, Kastle Therapeutics